HRH3 and spindle cell hemangioma: In addition, the H3R antagonist/inverse agonist MK-0249 (10 mg once daily) failed to be superior to placebo in the treatment of cognitive impairment in patients with SCH and following medications for 4 weeks (Egan et al., 2013).